Lumacaftor

鲁玛卡托

Report date: 2024/05/17 10:16:14
NME

Base Information

Drug NameLumacaftor
Drug Alias NameLumacaftor monotherapy卢玛卡托芦马卡托VRT-826809VX-809 +[6
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCystic fibrosis transmembrane conductance regulator modulators
TargetsCystic fibrosis transmembrane conductance regulator
Therapy Area/IndicationsCystic FibrosisHepatic Insufficiency
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[17
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
China Registration ClassN/A

Develop Information

Inactive CompaniesBayer AG
Active IndicationsCystic Fibrosis
Inactive IndicationsHepatic Insufficiency

Other Information

ATC CodeN/A